T80.311D ABO incompatibility with delayed hemolytic transfusion reaction, subsequent encounter

Name of the Condition

• ABO incompatibility with delayed hemolytic transfusion reaction, subsequent encounter.

Summary

This condition describes a delayed immune-mediated adverse reaction that occurs after the transfusion of blood or blood products with incompatible ABO antigens, leading to hemolysis (destruction of red blood cells). It is a serious complication that can cause systemic effects, including organ damage and hemodynamic instability. The reaction is driven by pre-existing antibodies in the recipient that target antigens on the transfused red blood cells, typically manifesting days to weeks after transfusion. The "subsequent encounter" designation indicates this is a follow-up visit for the condition.

Causes

ABO incompatibility with delayed hemolytic transfusion reaction results from the transfusion of blood or blood products containing ABO antigens that do not match the recipient's blood type. This mismatch triggers an immune response, where the recipient's antibodies bind to the donor red blood cells, leading to their destruction (hemolysis). The reaction can occur with red blood cells, plasma, or platelets if ABO compatibility is not maintained during transfusion.

Risk Factors

• Transfusion of blood products without proper ABO typing or crossmatching
• Emergency transfusions where typing may be delayed
• Human error in blood product labeling or administration
• Use of pooled plasma products with mixed ABO types
• Transfusion of platelets or plasma from donors with incompatible ABO antigens

Symptoms

• Fever, chills, or rigors
• Flank pain or back pain
• Hemoglobinuria (dark urine)
• Jaundice (yellowing of the skin or eyes)
• Unexplained anemia or drop in hemoglobin levels
• Elevated bilirubin or lactate dehydrogenase (LDH) levels

Diagnosis

Diagnosis involves a combination of clinical evaluation and laboratory testing. A detailed transfusion history is critical to identify potential ABO incompatibility. Laboratory tests may include a direct antiglobulin test (DAT) to detect antibodies attached to red blood cells, a crossmatch to identify incompatible antibodies, and measurements of hemoglobin, bilirubin, and LDH to assess hemolysis. Imaging or other tests may be used to evaluate organ involvement if symptoms suggest complications.

Treatment Options

Treatment focuses on managing symptoms and preventing further complications. This may include discontinuing the transfusion, providing supportive care (e.g., fluids, monitoring vital signs), and addressing hemolysis with interventions like renal protection or managing electrolyte imbalances. In severe cases, additional therapies such as dialysis or blood product support may be necessary. The underlying cause (e.g., incorrect blood type) must be investigated to prevent recurrence.

Prognosis and Follow-Up

Prognosis depends on the severity of the reaction and the timeliness of treatment. Most patients recover with appropriate management, but severe cases can lead to organ damage or life-threatening complications. Follow-up care is essential to monitor for delayed effects, assess recovery, and ensure no further transfusion errors occur. Regular laboratory testing and clinical evaluations may be recommended to track hemoglobin levels and organ function.

Complications

• Acute kidney injury or renal failure
• Disseminated intravascular coagulation (DIC)
• Shock or hypotension
• Multi-organ dysfunction
• Death (in severe cases)

Lifestyle & Prevention

Prevention is key to avoiding ABO incompatibility reactions. This includes strict adherence to blood typing and crossmatching protocols, double-checking blood product labels before administration, and using standardized transfusion procedures. Patients with a history of transfusion reactions should have their blood type and antibody status documented clearly in their medical records. Educating healthcare staff on transfusion safety can reduce human error.

When to Seek Professional Help

Seek immediate medical attention if symptoms such as fever, chills, severe pain, dark urine, or jaundice occur after a blood transfusion. These may indicate a delayed hemolytic reaction. Prompt evaluation is necessary to prevent complications and initiate treatment. Follow-up with a healthcare provider is also recommended if symptoms persist or worsen after an initial transfusion.

Tips for Medical Coders

Code T80.311D is used for a subsequent encounter for ABO incompatibility with delayed hemolytic transfusion reaction. Document the encounter as a follow-up visit, and ensure the diagnosis is clearly linked to a prior transfusion event. Include details about the timing of symptoms (days to weeks post-transfusion) and any confirmatory testing (e.g., DAT, crossmatch) to support the code. Avoid using this code for acute reactions or initial encounters.